Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau PET imaging in the Dallas Lifespan Brain Study
NCT04080544Phase 2Completed
- Start
- Jan 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of flortaucipir in Alzheimer's disease (AD), No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.. Started Jan 2019; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT04080544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080544.